• To assess the effect that early detection of non-muscle-invasive bladder cancer (NMIBC) with Hexvix ® blue-light cystoscopy may have on early recurrence rates. • Additional endpoints included the proportion of patients with additional Ta/T1 lesions detected with blue-light, carcinoma in situ (CIS) lesions detected with blue-light, and the rate of false positives.
• This trial was a prospective, randomized, multi-center study.
• Eligible patients had suspected Ta/T1 bladder tumors and were considered at increased risk for recurrence. They were being treated at one of 28 centers in the USA, Canada (19) and Europe (9). • Randomization was performed centrally and stratified for patients presenting with initial and recurrent bladder cancer. • Patients were randomized into one of two treatment groups:
• White light group: Patients in this group underwent cystoscopy and mapping of bladder lesions with white light, followed by TURB. • Hexvix® group: Patients in this group underwent cystoscopy and mapping of bladder lesions with white light. A second randomization was then performed, with patients assigned to: • Discontinue involvement in study.
• Continue in the study: These patients underwent bladder mapping again with Hexvix® blue-light cystoscopy, followed by a TURB (where indicated) under white light and blue-light to assess completeness of resection. • Patients with histologically confirmed Ta or T1 tumors by a central pathology consensus read were followed up using white light cystoscopy at 3,6 and 9 months from initial resection until histologically confirmed recurrence.
779 patients were randomized.
Tumor detection
• Detection was assessed as a within-patient comparison in the Hexvix® group only.
• Additional Ta/T1 were seen in 16,4% of patients with Ta/T1 (47 of 286; p=0.001).
• In these patients, the worst stage and grade of tumors found per patient with Hexvix® blue-light cystoscopy was: TaG2 in 27 (57%), T1G2 in 1 (2%), TaG3 in 12 (26%) and T1G3 in 7 (15%). • 32% of patients with CIS were detected with Hexvix® only (13 of 41; p<0.0001).
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Compared with white light cystoscopy alone, Hexvix® blue-light cystoscopy used as an adjunct to white light cystoscopy significantly improves the detection of bladder cancer, leading to a more complete resection and significantly better disease-free survival.
• The rates of false positives were similar for white light and blue-light cystoscopy (11% and 10% for white light and 12% for blue-light cystoscopy). 
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